<DOC>
	<DOCNO>NCT00022230</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Biological therapy use different way stimulate immune system stop tumor cell grow . Combining chemotherapy biological therapy may kill tumor cell . PURPOSE : This phase I/II trial study side effect give chemotherapy together biological therapy see well work treat patient stage II stage III breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Biological Therapy Treating Patients With Stage II Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxic effect sequential paclitaxel ( taxane ) , doxorubicin , cyclophosphamide follow immunotherapy activate T cell , interleukin-2 , sargramostim ( GM-CSF ) patient high-risk stage II III breast cancer . - Determine disease-free survival overall survival patient treat regimen . - Determine immune function patient treat regimen . OUTLINE : Patients stratify accord number positive lymph node ( less 4 node vs 4-9 node vs 10 node ) , type taxane chemotherapy study ( paclitaxel v taxane ) , prior treatment 2 3 study chemotherapy agent ( yes v ) . Patients receive doxorubicin IV day 1 filgrastim ( G-CSF ) day 3-10 3 consecutive 14-day course . Patients receive paclitaxel another taxane IV day 1 G-CSF day 3-10 3 consecutive 14-day course . Patients receive cyclophosphamide IV day 1 G-CSF day 3-10 3 consecutive 14-day course . Patients enroll previously receive 2 3 chemotherapy drug may receive third . Treatment continue absence disease progression unacceptable toxicity . After recovery chemotherapy , patient undergo peripheral blood mononuclear cell ( PBMC ) collection . The PBMC treat ex vivo monoclonal antibody OKT3 form activate T cell ( ATC ) . The ATC expand 14 day interleukin-2 ( IL-2 ) . At 3-4 week PBMC collection , patient receive ATC IV 15-30 minute weekly 8 week . Patients also receive IL-2 subcutaneously ( SC ) daily sargramostim ( GM-CSF ) SC twice weekly begin 3 day first ATC infusion continue 7 day completion ATC therapy . Patients follow every 3 month 1 year annually thereafter . PROJECTED ACCRUAL : A total 40-60 patient accrue study within 4-5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage II III adenocarcinoma breast Highrisk disease At least 4 positive lymph node Fewer 4 positive lymph node consider highrisk one follow present : HER2/neupositive disease Enlarged axillary node Extra capsular extension tumor lymph node Dermal lymphatic invasion Vascular invasion Bilateral disease Familial breast cancer T4 locally advance disease Clinically chemosensitive prior paclitaxel ( taxane ) , doxorubicin , cyclophosphamide No relapse chemotherapy No clinical evidence brain metastasis Hormone receptor status : Estrogen progesterone receptor status know PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : Karnofsky 70100 % OR ECOG 02 Life expectancy : At least 3 month Hematopoietic : Granulocyte count least 1,500/mm^3 Platelet count least 50,000/mm^3 Hemoglobin great 8 g/dL Hepatic : Bilirubin le 1.5 time normal SGOT le 1.5 time normal Renal Creatinine le 1.8 mg/dL Creatinine clearance least 60 mL/min BUN less 1.5 time normal Cardiovascular : Ejection fraction least 45 % MUGA No uncontrolled significant cardiovascular disease No myocardial infarction within past year No significant congestive heart failure Pulmonary : FEV_1 least 60 % predict DLCO least 60 % predict FVC least 60 % predict Other : No malignancy except curatively treat squamous cell carcinoma situ cervix basal cell skin cancer No serious medical psychiatric illness would preclude study participation HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Prior standard chemotherapy anthracyclines combination chemotherapy involve combination taxanes , doxorubicin , and/or cyclophosphamide allow Endocrine therapy : No concurrent hormonal therapy breast cancer Concurrent hormonal therapy nondiseaserelated condition ( e.g. , insulin diabetes ) allow Concurrent steroid adrenal failure , septic shock , pulmonary toxicity allow Radiotherapy : Not specify Surgery : Prior complete resection tumor allow Other : Prior successful neoadjuvant therapy allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>